Why is lupus nephritis mortality trending up in the US, in contrast to overall SLE mortality? Race matters Urban location can make things worse I'm outside looking in but hope it's not too bold to say disparities affect whether you live or die from LN #ACR21 ABST0454 @RheumNow https://t.co/wmB9l9fFTT

Dr De Miguel on subclinical large vessel vasculitis in PMR. US assessment. 22% had subclinical GCA. 90% LVV, 10% cranial GCA. Abstr#0466 #ACR21 @RheumNow https://t.co/PDCynMAigi

#ACR21 #ACRbest @RheumNow Abst#0366 by Garrido-Cumbrera et al. looked at shows that three out of four European axSpA patients have difficulty in finding a job.

Interesting study on immune cell profiling in PsA pts ⭐️variability in T cell sub-populations in PsA pts ⭐️no difference in lymphocyte cell populations before/after therapy Abs#0056 https://t.co/16PYxaxT2S #ACR21 @RheumNow https://t.co/dWaJr7hJ1p

• Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Pa…

T2T in AxSpA? ASDAS-qCRP & ASDAS-CRP showed an almost perfect agreement w/ regard to dz activity categories (96%.) Quick ASDAS-qCRP can be used in real time to make clinical decisions. Abs 0374 #ACR21 #RheumNow @RheumNow https://t.co/opOyedQUaZ https://t.co/aeUEsW9HsX

• Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Qu…

Biologic dose tapering in #axialspondyloarthritis in 52% of patients if criteria are met (BASDAI)< 40, physician global score< 40 and no signs of disease activity the previous year, escalation to previous dose if there is a flare @RheumNow #ACR21 Abst#0364 https://t.co/4GntJ6jS11

• Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Rou…

Do RA autoantibodies incr the risk of MACE? In study of ~2000 pts, ⬆️ concentrations of RA-related autoantibodies assoc. w/ MACE and/or CVD-mortality. Autoantibodies may therefore directly contribute to excess CVD risk in RA... Abs#0269 #ACR21 @RheumNow https://t.co/ju3YCRonJt https://t.co/UcOMsYxVMP

• Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans w…

Which pt has more MIs post elective surgery? #ACR21 @RheumNow abst#0128

Finally a way to improve Fatigue in RMDs? PLUS it is non pharmaceutical and remote⚡️! Cognitive Behavioural approaches and Personalised Exercise Interventions: ⬇️ Fatigue Severity and Impact ⬆️ Sleep at 1yr in a multiarm RCT. #OP0462 @RheumNow #ACR2021 https://t.co/5buGCYb5Ut https://t.co/4Wz2VmcL3x

• Remotely Delivered Cognitive Behavioural and Personalised Exercise Intervention…

Winning Image Competition: Rheum Dz in Patients of Color: Dermatomyositis #ACR21 @rheumnow https://t.co/OFRDDgQqas

Erosive polyarticular chronic tophaceous gout Regional Winner of East Asia and Pacific Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/1wrNAhjsw6

SLE patients with +aPL was associated with: ➡️Nephritis ➡️Discoid rash ➡️Serositis ➡️Neurologic disorder Consider aPL and LAC status in patients w/these manifestations and whether anticoagulation/antiplatelets may be needed #ACR21 Abst#0077 @RheumNow

Juvenile dermatomyositis, with Gottren's and diffuse hyperpigmentation Regional Winner of Europe & Central Asia Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/vxayxgINa8

Lichenoid cutaneous lupus erythematosus mimicking acanthosis nigricans Regional Winner of Latin America and Caribbean Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/4oAXIClwsm

#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19. ▶️150 mg RZB vs Placebo ⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI ⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn ⭐️No safety signal https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd

• https://bit.ly/2ZWO0rV